$QLGN
Qualigen Therapeutics Inc
PRICE
$0.5241 βΌ-1.503%
Last Close
VOLUME
251,454
DAY RANGE
0.5212 - 0.5555
52 WEEK
0.45 - 3.12
Key Metrics
Market Cap
18.78 M
Beta
1.15
Avg. Volume
466.12 K
Shares Outstanding
35.30 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-16
Next Dividend Date
Company Information
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSβ’. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC.
CEO: Andrew Ritter
Website: www.qualigeninc.com
HQ: 1880 Century Park E Ste 1000 Los Angeles, 90067 California
Related News